MX2023012728A - Esteroide neuroactivo para el tratamiento del trastorno depresivo mayor y la depresion posparto en una mujer lactante. - Google Patents

Esteroide neuroactivo para el tratamiento del trastorno depresivo mayor y la depresion posparto en una mujer lactante.

Info

Publication number
MX2023012728A
MX2023012728A MX2023012728A MX2023012728A MX2023012728A MX 2023012728 A MX2023012728 A MX 2023012728A MX 2023012728 A MX2023012728 A MX 2023012728A MX 2023012728 A MX2023012728 A MX 2023012728A MX 2023012728 A MX2023012728 A MX 2023012728A
Authority
MX
Mexico
Prior art keywords
depressive disorder
major depressive
subject
postpartum depression
neuroactive steroid
Prior art date
Application number
MX2023012728A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Jay Kanes
James Doherty
Handan Gunduz-Bruce
Robert Alfonso Lasser
Jeffrey Martin Jonas
Jeffrey A Wald
Amy E Bullock
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2023012728A publication Critical patent/MX2023012728A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
MX2023012728A 2021-04-29 2022-04-29 Esteroide neuroactivo para el tratamiento del trastorno depresivo mayor y la depresion posparto en una mujer lactante. MX2023012728A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163181807P 2021-04-29 2021-04-29
PCT/US2022/026908 WO2022232494A1 (en) 2021-04-29 2022-04-29 Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female

Publications (1)

Publication Number Publication Date
MX2023012728A true MX2023012728A (es) 2023-11-08

Family

ID=81748326

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012728A MX2023012728A (es) 2021-04-29 2022-04-29 Esteroide neuroactivo para el tratamiento del trastorno depresivo mayor y la depresion posparto en una mujer lactante.

Country Status (9)

Country Link
US (1) US20240216396A1 (https=)
EP (1) EP4329769A1 (https=)
JP (1) JP2024515830A (https=)
CN (1) CN117580580A (https=)
AU (1) AU2022267304A1 (https=)
CA (1) CA3217866A1 (https=)
IL (1) IL307980A (https=)
MX (1) MX2023012728A (https=)
WO (1) WO2022232494A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015002252A (es) 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス, インコーポレイテッド 19−ノルc3,3−ジ置換c21−n−ピラゾリルステロイドおよびその使用方法
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
TWI904593B (zh) 2016-08-23 2025-11-11 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3720867A1 (en) 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス, インコーポレイテッド 19−ノルc3,3−ジ置換c21−n−ピラゾリルステロイドおよびその使用方法
TWI904593B (zh) 2016-08-23 2025-11-11 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3678670A1 (en) * 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
CA3103421A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
CN113939298A (zh) * 2018-12-14 2022-01-14 普拉西斯精密医药公司 用于治疗抑郁症的方法
US20230285417A1 (en) 2020-07-20 2023-09-14 Sage Therapeutics, Inc. Formulations of 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof

Also Published As

Publication number Publication date
IL307980A (en) 2023-12-01
JP2024515830A (ja) 2024-04-10
WO2022232494A1 (en) 2022-11-03
AU2022267304A1 (en) 2023-11-02
CN117580580A (zh) 2024-02-20
EP4329769A1 (en) 2024-03-06
CA3217866A1 (en) 2022-11-03
US20240216396A1 (en) 2024-07-04

Similar Documents

Publication Publication Date Title
MX2023012728A (es) Esteroide neuroactivo para el tratamiento del trastorno depresivo mayor y la depresion posparto en una mujer lactante.
NZ719137A (en) Combination of two antivirals for treating hepatitis c
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
ATE479469T1 (de) Vorrichtung zum synchronisierten atem für die behandlung von geweben unter atembewegung
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
MX2023012727A (es) Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto.
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
SG10201807789WA (en) Vaginal composition and use thereof
WO2020092618A9 (en) Methods of treating depression, anxiety and sexual dysfunction using the compound pimavanserin
TW200602030A (en) Use of loteprednol etabonate for the treatment of dry eye
MX2024011142A (es) Tratamiento de neurofibromas cutaneos con mirdametinib.
RU2012108656A (ru) Применение 4-аминопиридина для улучшения состояния при нейрокогнитивном и/или нейропсихиатрическом нарушении у пациентов с демиелинизирующими и другими заболеваниями нервной системы
TN2015000480A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
DE60111025D1 (de) Verwendung von Topiramat zur Behandlung und Diagnostizierung von Atemstörungen während des Schlafens und Mittel zur Durchführung der Behandlung und Diagnose
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2023003258A (es) Tratamiento de enfermedades mediadas por nf-kb.
CA3168207A1 (en) Cellular uptake
CN202526532U (zh) 新生儿呼吸暂停复苏装置
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
MX2026000090A (es) Lemborexant para el tratamiento de problemas del sueño
CN214710656U (zh) 髂骨移植术后髂部加压裤
CN210277969U (zh) 一种药包披肩
Van der Walt et al. Fixation of mandible fractures: A simplified method
MX2025009650A (es) Uso del acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxilico en el tratamiento de la esclerosis multiple
MX2025005174A (es) Formulacion oral de derivado de n-piridinilacetamida para tratar la enfermedad pulmonar intersticial